Ledowsky Carolyn Jane, Schloss Janet, Steel Amie
Endeavour College of Natural Health, now at University of Technology Sydney, Faculty of Health, Australia.
Southern Cross University, Natural Centre for Naturopathic Medicine, Lismore, NSW, Australia.
Explor Res Clin Soc Pharm. 2023 May 8;10:100277. doi: 10.1016/j.rcsop.2023.100277. eCollection 2023 Jun.
Over 48.5 million couples are reported with infertility worldwide. Health policy recommends folic acid in women of childbearing age, particularly in preconception and pregnancy which results in women purchasing over-the-counter prenatal multivitamins containing folic acid through pharmacies and other retail outlets. Emerging studies are investigating whether other forms of supplemental folate are more suitable, particularly for those with methylenetetrahydrofolate reductase () polymorphisms. This case series aimed to document variations in forms and dosage of folate prescribed by Australian practitioners to patients with diagnosed infertility and polymorphisms.
Australian practitioners were invited to complete a retrospective case report form for patients that presented with unexplained infertility. This case report form documented the form and dose of folate that practitioners were prescribing to their infertility patient with MTHFR polymorphisms, together with their fertility history.
Six practitioners submitted case information for 12 patients with diagnosed infertility and polymorphisms. All patients had been advised by their practitioner to remove folic acid in supplemental form and were prescribed 5-methyltetrahydrofolate (5-MTHF) or a combination of 5-MTHF and folinic acid, at higher doses than the Australian recommended dose (mean daily maximum prescribed dose: 2325μg). Eleven patients conceived within the treatment period (average treatment of one year) and ten were reported as having a live birth.
This case series has highlighted clinical practices that vary from the recommendations by Australian policy. Further research is required to verify the clinical importance of variations in folate prescriptions for women with polymorphisms and how folate recommendations may need to change depending on these polymorphisms. This has direct relevance to those prescribing at the pharmacy and retail level, specifically pharmacists and pharmacy assistants.
据报道,全球有超过4850万对夫妇患有不孕症。卫生政策建议育龄妇女补充叶酸,尤其是在孕前和孕期,这导致女性通过药店和其他零售渠道购买含叶酸的非处方产前多种维生素。新兴研究正在调查其他形式的补充叶酸是否更合适,特别是对于那些患有亚甲基四氢叶酸还原酶(MTHFR)基因多态性的人。本病例系列旨在记录澳大利亚医生给诊断为不孕症且有MTHFR基因多态性的患者所开叶酸的形式和剂量差异。
邀请澳大利亚医生为患有不明原因不孕症的患者填写一份回顾性病例报告表。该病例报告表记录了医生给患有MTHFR基因多态性的不孕症患者所开叶酸的形式和剂量,以及他们的生育史。
六位医生提交了12例诊断为不孕症且有MTHFR基因多态性患者的病例信息。所有患者的医生都建议他们停用补充形式的叶酸,并开了5-甲基四氢叶酸(5-MTHF)或5-MTHF与亚叶酸的组合,剂量高于澳大利亚推荐剂量(平均每日最大处方剂量:2325μg)。11名患者在治疗期内(平均治疗一年)怀孕,据报告10名患者活产。
本病例系列突出了与澳大利亚政策建议不同的临床实践。需要进一步研究来验证叶酸处方差异对患有MTHFR基因多态性女性的临床重要性,以及叶酸建议如何根据这些基因多态性而改变。这与在药房和零售层面开处方的人员直接相关,特别是药剂师和药房助理。